帕利珠单抗报销标准与新生儿 RSV 住院治疗：区域性回顾性研究。
Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review.
机构信息
Department of Epidemiology, Regional Health Service, Azienda Sanitaria Locale Roma 1, Roma, Italy.
Pediatrics, AUSL Ravenna, Ravenna, Italy.
出版信息
BMJ Paediatr Open. 2021 Mar 1;5(1):e000985. doi: 10.1136/bmjpo-2020-000985. eCollection 2021.
In Italy, reimbursement restrictions regarding palivizumab prophylaxis approved in 2016 have been revoked in 2017, restoring use in infants with Gestational Age (GA) >29 weeks. Respiratory Syncytial Virus (RSV) hospitalisations and prevalence of palivizumab use in infants aged <6 months during five seasons (2014-2019), were considered according to different GA. Although RSV hospitalisations rate showed no significant changes, during different seasons in all GA, lower prevalence of palivizumab use in 2016 (0.8% vs 0.3%), returned to a higher level following the revoke of restrictions. Changes in reimbursement criteria were not associated with neonatal RSV hospitalisations rate but with a significant impact on palivizumab use.
在意大利，2016 年批准的帕利珠单抗预防接种的报销限制已于 2017 年取消，恢复了对胎龄（GA）＞29 周的婴儿的使用。根据不同的 GA，考虑了五个季节（2014-2019 年）中＜6 个月的婴儿的呼吸道合胞病毒（RSV）住院率和帕利珠单抗的使用情况。尽管 RSV 住院率在所有 GA 的不同季节均无显著变化，但 2016 年帕利珠单抗的使用率较低（0.8%比 0.3%），在限制取消后又恢复到较高水平。报销标准的变化与新生儿 RSV 住院率无关，但对帕利珠单抗的使用有显著影响。
Zotero 插件